Extrait

Background and study aims Senile warts are benign skin tumours. They are removed by invasive, unpleasant methods (curettage, cryotherapy, laser, surgery) with certain risks (e.g. infection, depigmentation). This clinical proof of concept study aims to assess the efficacy of an artemether topical formulation in the treatment of senile warts. Who can participate? Each participant must have at least 8 flat or slightly elevated senile warts. What does the study involve? The test product will be applied twice daily for up to 8 weeks. Five lesions per study participant will be treated with study medication and 3 will serve as reference lesions. The assessment of efficacy will be performed on the photographs taken at the beginning and the treatment and study end by applying a regression score and by measuring the longest axis of lesion. What are the possible benefits and risks of participating? The potential benefit for participants is a painless, non-invasive treatment leading to regression or clearance of seborrheic keratosis. Development of adverse events like pruritis, erythema are possible risks associated with the treatment. Where is the study run from? The study will be carried out in a dermatology clinic. When is the study starting and how long is it expected to run for? From February 2015 to July 2015. Who is funding the study? EpiPharm AG Who is the main contact? Dr Rosemarie Sift Carter

Critère d'inclusion

• Seborrheic keratosis

Liens

• isrctn
• ictrp